🇺🇸 FDA

Intelligence · Clinical Pipeline

Metabolic & obesity R&D Pipeline

GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Programs
755

Quick answer

Metabolic & obesity: NovaPharmaNews indexes 755 metabolic & obesity clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. GLP-1, metabolic disease, obesity, and diabetes pipeline programs with sponsor and trial ID cross-links.

Top sponsors

Page 2 of 16

  1. Eloralintide, Eloralintide, Eloralintide, Placebo to match LY, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity, Sleep Apnea, Obstructive

    phase 3 small molecule active

    1 trial

  2. Eloralintide, Eloralintide, Placebo to match LY, Eloralintide, Eloralintide

    Eli Lilly Co.

    Overweight, Obesity

    phase 3 small molecule active

    1 trial

  3. Eloralintide, Placebo to match LY, Eloralintide, Eloralintide, Eloralintide

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  4. Empagliflozin 10 MG

    Hospital Authority, Hong Kong

    Diabetic Nephropathies

    phase 3 small molecule terminated

    1 trial

  5. Empagliflozin 20 mg

    COLLEGIUM PHARMACEUTICAL, INC

    Metabolic Syndrome

    phase 3 small molecule active

    1 trial

  6. Faricimab

    Hoffmann-La Roche

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  7. Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  8. Fasiglifam (TAK-875)

    Takeda

    Diabetes Mellitus, Type 2

    phase 3 small molecule terminated

    1 trial

  9. Faster-acting insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  10. Finerenone (BAY94-8862)

    Bayer HealthCare AG

    Diabetic Kidney Disease

    phase 3 small molecule completed

    1 trial

  11. Finerenone, Placebo, Placebo, BAY 94-8862

    Bayer AG

    Non-diabetic chronic kidney disease

    phase 3 small molecule active

    1 trial

  12. Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  13. Glimepiride

    Janssen Cilag International NV

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  14. Glucagon

    Xeris Biopharma Holdings

    Diabetes Mellitus, Type 1

    phase 3 small molecule completed

    1 trial

  15. HS-20094 Injection

    Jian Li

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  16. Human Insulin Inhalation Powder

    Eli Lilly and Company

    Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  17. Identical to kai-9531 solution for injection without active drug, KAI-9531, KAI-9531, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  18. Inhaled Human Insulin

    Nektar Therapeutics UK Limited

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  19. Insulin Degludec and Insulin Aspart

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Diabetes

    phase 3 small molecule completed

    1 trial

  20. Insulin degludec/insulin aspart

    Novo Nordisk A/S

    Diabetes

    phase 3 small molecule completed

    1 trial

  21. Insulin glargine/Lixisenatide (HOE901/AVE0010)

    Sanofi Pasteur

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  22. Insulin icodec

    Novo Nordisk A/S

    Diabetes, Type 2

    phase 3 small molecule completed

    1 trial

  23. Intravitreal Aflibercept Injection (IAI)

    Regeneron UK Limited

    Proliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  24. Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 3 small molecule completed

    1 trial

  25. Intravitreal aflibercept injection [IAI]

    Regeneron UK Limited

    Nonproliferative Diabetic Retinopathy

    phase 3 small molecule completed

    1 trial

  26. Jardiance 10 mg film-coated tablets, Placebo matching vicadrostat, BI 690517

    Boehringer Ingelheim

    Type 2 diabetes, hypertension, cardiovascular disease

    phase 3 small molecule active

    1 trial

  27. KAI-9531

    Kailera Therapeutics

    Obesity With Diabetes

    phase 3 small molecule active

    1 trial

  28. KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    3 trials

  29. KAI-9531, KAI-9531, Identical to kai-9531 solution for injection without active drug, KAI-9531

    Kailera Therapeutics

    Obesity

    phase 3 small molecule active

    1 trial

  30. Khalas dates

    United Therapeutics Europe Ltd

    Diabetes Mellitus

    phase 3 other completed

    1 trial

  31. LMF237 50/250 mg

    Novartis Pharmaceuticals

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  32. LY2189265

    United Therapeutics Europe Ltd

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  33. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen

    NovoThirteen

    Type 1 Diabetes

    phase 3 small molecule active

    1 trial

  34. Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen, insulin icodec 700 U/mL PDS290

    NovoThirteen

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  35. Lapaquistat acetate and lipid-lowering therapy

    Takeda

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  36. Lifestyle modification

    Takeda

    Type 2 Diabetes

    phase 3 other completed

    1 trial

  37. Linagliptin

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    3 trials

  38. Liraglutide placebo, Saxenda 6 mg/mL solution for injection in pre-filled pen

    NovoThirteen

    Obesity

    phase 3 small molecule active

    1 trial

  39. METFORMIN

    Pari Pharma GmbH

    Type 2 Diabetes complete remission after bariatric surgery under antidiabetic drug

    phase 3 small molecule active

    1 trial

  40. METFORMIN , DAPAGLIFLOZIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  41. METFORMINE ARROW LAB 1000 mg, comprimé pelliculé sécable, Placebo de metformine Arrow Lab 1000 mg - Composition: Cellulose microcristalline; Lactose monohydraté; Stéarate de magnésium (vegetable origin); Opadry TM 07F28588; Eau purifiée

    Pari Pharma GmbH

    Vascular calcification and type 1 diabetes

    phase 3 small molecule active

    1 trial

  42. MGL-3196

    Madrigal Pharmaceuticals EU Limited

    NASH - Nonalcoholic Steatohepatitis

    phase 3 small molecule active

    1 trial

  43. MGL-3196 80 mg oral, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 60 mg film-coated tablet, MGL-3196 60 mg oral, MGL-3196 100 mg oral, Matching placebo MGL-3196 100 mg film-coated tablet

    Madrigal Pharmaceuticals EU Limited

    Non-alcoholic Steatohepatitis (NASH) Cirrhosis

    phase 3 small molecule active

    1 trial

  44. Maridebart cafraglutide

    Amgen

    Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight

    phase 3 small molecule active

    1 trial

  45. Matching placebo MGL-3196 60 mg film-coated tablet, Matching placebo MGL-3196 80 mg film-coated tablet, Matching placebo MGL-3196 100 mg film-coated tablet., MGL-3196 60 mg oral, MGL-3196 100 mg oral, MGL-3196 80 mg oral

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Steatohepatitis (NASH)

    phase 3 small molecule active

    1 trial

  46. Metformin

    AstraZeneca

    Type 2 Diabetes

    phase 3 small molecule completed

    1 trial

  47. Metformin on top of intensive insulin therapy

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    1 trial

  48. Metformin plus pioglitazone

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many metabolic & obesity pipeline programs are tracked?

755 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.